Physician profile
Daniel Bell
NPI 1609861798
$6,777.97
in general payments reported to CMS, 2019-2025
49 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $218 · 2021: $608 · 2022: $980 · 2023: $1,129 · 2024: $1,287 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,529.86 | 2021-2025 | Duopa, Qulipta, Ubrelvy |
| Pfizer INC. | $504.89 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $463.41 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $448.32 | 2019-2025 | Nuplazid |
| Genzyme Corporation | $420.38 | 2019-2023 | |
| Ge Healthcare | $416.31 | 2019-2025 | |
| Celgene Corporation | $337.90 | 2022-2025 | Zeposia |
| Allergan, INC. | $274.97 | 2019-2022 | |
| Integra Lifesciences Corporation | $269.02 | 2019-2021 | |
| Amgen INC. | $155.31 | 2019-2025 | Uplizna |
| Ucb, INC. | $141.71 | 2019-2025 | Zilbrysq, Rystiggo |
| Lundbeck LLC | $140.61 | 2024-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $137.53 | 2023-2025 | Ultomiris, Soliris |
| Horizon Therapeutics Plc | $86.35 | 2022-2023 | Uplizna |
| Biogen, INC. | $85.87 | 2021-2025 | Vumerity |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.